New triple therapy aims to tame type 2 diabetes
NCT ID NCT07026968
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding two new drugs—prusogliptin and dapagliflozin—to standard metformin can improve blood sugar control in adults with type 2 diabetes. About 815 participants who are not well-controlled on metformin alone will receive either the triple combination or a placebo plus metformin. The main goal is to see if the combo lowers HbA1c (a key blood sugar measure) more effectively after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prusogliptin, dapagliflozin, and metformin
What this could lead to
If successful, this triple-drug combination could offer a new, more effective option for managing blood sugar in people with type 2 diabetes who don't get enough help from metformin alone.
What could go wrong
This is a phase 3 trial, but results are not yet available. The combination may not prove significantly better than existing treatments, and side effects from multiple drugs could be a concern.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
No. 896, Zhongshan East Road, High-tech Industrial Development Zone
Shijiazhuang, Hebei, 050035, China